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Anemia management is getting complex. The evidence that we use to guide ane-mia therapy is based on observational studies as well as clinical trials. The 
observational studies have uniformly demon-
strated that persons with higher hemoglobin levels 
enjoy better outcomes, including fewer hospitali-
zations and longer survival.1 Randomized control-
led trials, on the other hand, paint a different and 
far more complex picture.
The Normalization of Hematocrit Trial strongly 
suggested that targeting a normal hematocrit in 
patients with end-stage renal disease resulted in 
an increased risk of myocardial infarction and 
mortality.2 After the completion of this trial, all 
patients in the study were treated to a hematocrit 
of 30% and followed for one year. When patients in 
the high-hemoglobin-target group were treated to 
the lower goal, their mortality rate was no longer 
greater than that of the patients in the other arm 
but instead was identical to that of those who had 
previously had the lower goal.3 However, the most 
confusing point is that in spite of the fact that tar-
geting a higher goal resulted in a greater risk, those 
patients who could actually achieve the higher 
hematocrit had the lowest mortality of all.
Ten years later, three additional randomized 
trials testing different hemoglobin targets provide 
superficially different but amazingly similar results. 
The Cardiovascular Risk Reduction by Early Ane-
mia Treatment with Epoetin Beta study (CREATE) 
randomized chronic kidney disease patients to a 
hemoglobin level either between 13.0 and 15.0 g/
dl or between 10.5 and 11.5 g/dl using epoetin-
beta.4 No difference in the frequency or timing 
of multiple cardiovascular outcomes was seen 
between arms. The Correction of Hemoglobin and 
Outcomes in Renal Insufficiency study (CHOIR) 
randomized chronic kidney disease patients to a 
hemoglobin level of either 13.5 or 11.3 g/dl using 
epoetin-alfa.5 There were, however, significant 
differences between groups in the frequency or 
timing of congestive heart failure hospitalization, 
myocardial infarction, stroke, and death. Patients 
randomized to the higher-hemoglobin arm had a 
34% higher risk for these events (P = 0.03).
Key opinion leaders in nephrology discussed the 
differences between these latter two studies with 
the observation that subjects in CHOIR required 
significantly higher doses than those in CREATE.6 
Subsequent analyses in CHOIR strongly suggested 
a relationship between higher-dose epoetin-alfa 
and cardiovascular outcomes that may be direct 
rather than merely a marker of comorbidity.7 
One could conjecture that if higher doses were 
the mechanism by which CHOIR demonstrated 
harm, it would be predictable that the smaller 
doses needed in CREATE would not result in the 
demonstration of the same risk. Concurrently 
with CHOIR, it was established that patients with 
malignancy treated with epoetin-alfa had a greater 
risk of cancer progression or recurrence and death 
than those who were not treated, adding to simi-
lar concerns regarding the direct toxicities of the 
medication itself.8
Finally, the Trial to Reduce Cardiovascular 
Events With Aranesp Therapy (TREAT) rand-
omized patients with diabetes mellitus and chronic 
kidney disease to treatment of anemia with dar-
bepoetin to a hemoglobin level of 13.0 g/dl versus 
placebo. In this trial, with the exception of one 
of the end points in the composite, no benefit or 
harm was seen in the group receiving active treat-
ment.9 However, quite notably, the risk of stroke 
in the treated group was twice that seen in the pla-
cebo arm (hazard ratio 1.92, P < 0.001). Further, 
the risk of death among patients with a preexisting 
history of cancer was significantly higher in the 
treated as compared with the placebo patients.
Although superficially different from the 
prior trials, these trials are actually all parts of 
the complex puzzle that is finally taking shape. 
The conclusions of CHOIR and CREATE may 
not contradict each other. If a dose–risk rela-
tionship between epoetin-alfa and outcomes 
exists, the fact that patients in CHOIR required 
higher doses would be the mechanism by which 
the outcome difference was seen. Further, the 
conclusions of TREAT and CHOIR may not 
contradict each other. In a subgroup analysis 
of CHOIR, patients with diabetes mellitus ran-
domized to 13.5 as compared with 11.3 g/dl 
experienced no difference in their risk of car-
diovascular events or death.10 Those patients 
without diabetes mellitus experienced rela-
tive outcomes more reflective of the primary 
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intention-to-treat analysis, whereby patients ran-
domized to the higher goal were at greater risk.
The message to clinicians is complex and will 
likely continue to evolve as additional analyses 
are explored and studies done. If a relationship 
between increasing dose and risk is confirmed, 
one could hypothesize that in high-risk popu-
lations such as those with diabetes mellitus, the 
mechanism of this dose–risk relationship does 
not clinically manifest as fast as the accelerated 
cardiovascular risk among this high-risk group. 
In other words, patients with diabetes have 
stronger competing risks, making any risk asso-
ciated with epoetin-alfa or darbepoetin therapy 
(except, of course, that of stroke) statistically 
nonapparent.
The message to legislators, third-party pay-
ers, and anyone who seeks to establish quality 
benchmarks is, however, far more simple. Clini-
cal practice guidelines are written by clinicians 
to guide clinical care.11 Their goals are to dis-
seminate the best evidence available and to pro-
vide goals for therapeutic decisions of physicians 
and health-care providers to act on those aspects 
of patient health over which they have control. 
The guidelines present hemoglobin targets as 
goals and are supplemented with information 
to the clinician on how to recognize, diagnose, 
and attempt to treat those patients who cannot 
achieve those goals. It must be underscored that 
the guidelines as well as the clinical commu-
nity recognize that separate and distinct from 
the aspects of treatment over which health-care 
providers have control are a host of mechanisms 
outside their control, such as the inflammatory 
state of a patient, that affect the ability of patients 
to achieve their target hemoglobin level.
If higher doses of epoetin-alfa do confer a cardio-
vascular risk, the approach to grading the quality of 
anemia management using a simple threshold such 
as that proposed as a quality incentive program 
under the new bundle to begin in 2011 may not be 
appropriate. Operating under the assumption that 
small numbers of hyporesponsive patients drove 
the risk in CHOIR, if higher doses of epoetin-alfa 
are not administered to a patient who is hypo-
responsive for reasons outside the physician’s con-
trol, the patient will obviously not experience the 
increased risk associated with those doses. How-
ever, the health-care professional or team will be 
penalized as not providing quality care, when 
in fact they are operating in the evidence-based 
manner that should be incentivized.
In the short term, clinicians should continue to 
treat according to the package insert, obtaining 
guidance from the clinical practice guidelines, 
and be cognizant of the potential for an epoetin-
alfa dose–risk relationship in the care of indi-
vidual patients who require the largest doses. 
Those who seek to establish performance mark-
ers, though, have urgent decisions to make. The 
contribution of comorbidities and illness to dose 
requirements and to the failure to achieve hemo-
globin targets must be recognized as being often 
outside of a physician’s ability to effectively influ-
ence and cannot be ignored. Unless the quality 
improvement markers such as those identified in 
the draft rule for the new bundled payment12 are 
altered to reflect the complexities of the relation-
ships that we are now beginning to understand, 
clinicians will find themselves caught between 
the science and the payment. That difficult posi-
tion is certainly not the motivation intended to 
incentivize quality care.
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